Resmed Cdi revenue and financials
$31.90Change from previous close: −0.31%Absolute change: −$0.10
In the fiscal year ended June 2026, Resmed Cdi reported revenue of $5.65B (+9.85% year over year). Net income was $1.52B, a net margin of 26.9%.
Fiscal year ending in June. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +9.85%
- FY to Jun 2026 vs FY to Jun 2025
- Net income growth
- +8.75%
- FY to Jun 2026 vs FY to Jun 2025
- Net margin
- 26.9%
- FY to Jun 2025: 27.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 455 | 554 | 340 | 457 | 539 | — |
| Depreciation and amortization | 55.1 | 69.0 | 62.3 | 57.7 | 74.3 | — |
| Capital expenditure | -57.3 | -39.6 | -34.6 | -45.8 | -33.8 | — |
| Investing cash flow | -384 | -58.0 | -50.9 | -52.6 | -134 | — |
| Financing cash flow | -263 | -255 | -258 | -230 | -164 | — |
| Dividends paid | -87.1 | -87.2 | -87.6 | -87.8 | -77.6 | — |
| Share repurchases | -200 | -175 | -175 | -150 | -100 | — |
| Debt issued | — | — | — | — | 0.0 | 0.0 |
| Debt repaid | -5.0 | 0.0 | -5.0 | 0.0 | -5.0 | — |
| Effect of exchange rates | 0.9 | 2.6 | 2.8 | -0.1 | 35.6 | — |
| Net change in cash | -192 | 241 | 30.5 | 174 | 241 | — |
| Free cash flow | 397 | 515 | 305 | 412 | 505 | — |